Scholarlink

<p>The threat of antibiotic-resistant bacteria is rapidly escalating, creating an urgent need for new types of antimicrobials. Although most antibiotics act by disrupting essential cellular processes, such as cell division, replication, transcription, and translation, few novel agents targeting these pathways have been discovered in recent years. So, we pursued a different strategy by searching for molecules that may hyperactivate the ClpP protease, leading to bacterial cell death. ADEP4, a peptide antibiotic, exemplifies this approach by inducing uncontrolled protein degradation via ClpP. Based on key binding sites of ADEP4 on ClpP, we conducted in silico screening using molecular docking, structural chemistry, and pharmacokinetic parameters, primarily evaluating binding affinity (kcal/mol). We identified Birabresib as a promising candidate using this approach. Here, we demonstrate that Birabresib effectively inhibits Gram-positive bacteria, exhibits synergy with the antibiotic rifampicin, and has limited cytotoxicity on the human cell line tested.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Repurposing Birabresib to target Gram‑positive bacteria

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月11日

查看全文
  • Hazera Khatun Koly,
  • Roha Razzaq,
  • Tahmina Hossain,
  • Nicholas C. Butzin

摘要

The threat of antibiotic-resistant bacteria is rapidly escalating, creating an urgent need for new types of antimicrobials. Although most antibiotics act by disrupting essential cellular processes, such as cell division, replication, transcription, and translation, few novel agents targeting these pathways have been discovered in recent years. So, we pursued a different strategy by searching for molecules that may hyperactivate the ClpP protease, leading to bacterial cell death. ADEP4, a peptide antibiotic, exemplifies this approach by inducing uncontrolled protein degradation via ClpP. Based on key binding sites of ADEP4 on ClpP, we conducted in silico screening using molecular docking, structural chemistry, and pharmacokinetic parameters, primarily evaluating binding affinity (kcal/mol). We identified Birabresib as a promising candidate using this approach. Here, we demonstrate that Birabresib effectively inhibits Gram-positive bacteria, exhibits synergy with the antibiotic rifampicin, and has limited cytotoxicity on the human cell line tested.